Journals / Journal of Human Rhythm / 2026 / Cilt: 5 Sayı: 2

Relationship Between Bilirubin Levels and Heart Rate Recovery in Polycystic Ovary Syndrome Patients

Pages
74–85
Publication Date
2019-06-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aim: Bilirubin is a final product of heme metabolism 

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Bilirubin is a final product of heme metabolism 
📊
Key Findings & Data:Aim: Bilirubin is a final product of heme metabolism 
💡
Conclusion & Impact:Aim: Bilirubin is a final product of heme metabolism 
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Bilirubin · heart rate recovery · polycystic ovary syndrome

Abstract

Aim: Bilirubin is a final product of heme metabolism 

🔖

Cite This Article

Asoğlu, E. (2019). Relationship Between Bilirubin Levels and Heart Rate Recovery in Polycystic Ovary Syndrome Patients. Journal of Human Rhythm, Cilt: 5 Sayı: 2, 74–85. https://ajindex.com/articles/1592420

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. erences 1. Sanchón R, Gambineri A, Alpañés M, Martníez-Garcaí MÁ, et al. HF. Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod 2012
  2. 1209–16. 2. Barber TM, Franks S. The link between polycystic ovary syndrome and both {Type} 1 and {Type} 2 diabetes mellitus: what do we know today? Women’s Heal 2012
  3. 147–54. 3. Bentley-Lewis R, Seely E, Dunaif A. Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin 2011
  4. 433–49. 4. Chang C-Y, Chen M-J, Yang W-S, Yeh C-Y, et al. Hypoadiponectinemia: A useful marker of dyslipidemia in women with polycystic ovary syndrome. Taiwan J Obstet Gynecol 2012
  5. 583–90. 5. Yaralı H, Yıldırır A, Aybar F, Kabakçı G, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001
  6. 511–6. 6. Verit FF, Erel O. Oxidative stress in nonobese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Invest 2008
  7. 233–9. 7. Mohamadin AM, Habib FA, Elahi TF. Serum paraoxonase 1 activity and oxidant/antioxidant status in {Saudi} women with polycystic ovary syndrome. Pathophysiology 2010
  8. 189–96. 8. Enli Y, Fenkci SM, Fenkci V, Oztekin O. Serum {Fetuin}-{A} levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 2013
  9. 1036–9. 9. Hoeldtke RD, Bryner KD, VanDyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 2011
  10. 19–28. 10. Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 2004
  11. 2178–83. 11. Imai K, Sato H, Hori M, Kusuoka H, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994
  12. 1529–35. 12. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999
  13. 1351–7. 13. Schwartz PJ, La MTR, Vanoli E. Autonomic nervous system and sudden cardiac death. {Experimental} basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992
  14. I77--91. 14. Tekin G, Tekin A, Kılıçarslan EB, Haydardedeoğlu B, et al. Altered autonomic neural control of the cardiovascular system in patients with polycystic ovary syndrome. Int J Cardiol 2008
  15. 49–55. 15. Giallauria F, Palomba S, Manguso F, Vitelli A, et al. Abnormal heart rate recovery after maximal cardiopulmonary exercise stress testing in young overweight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008
  16. 88–93. 16. Jansen T, Daiber A. Direct antioxidant properties of bilirubin and biliverdin. {Is} there a role for biliverdin reductase? Front Pharmacol 2012
  17. Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012
  18. 77–83. 18. Oh SW, Lee ES, Kim S, Na KY, et al. Bilirubin attenuates the renal tubular injury by inhibition of oxidative stress and apoptosis. BMC Nephrol 2013
  19. Gul M, Uyarel H, Ergelen M, Akgul O, et al. Prognostic value of total bilirubin in patients with {ST}-segment elevation acute myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2013
  20. 166–71. 20. Turfan M, Duran M, Poyraz F, Yayla C, et al. Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease. Coron Artery Dis 2013
  21. 29–32. 21. Katsiki N, Karagiannis A, Mikhailidis DP. Diabetes, bilirubin and amputations: is there a link? Diabetologia 2013
  22. 683–5. doi:10.1007/s00125-013-2840-1. 22. Choi S-W, Lee Y-H, Kweon S-S, Song H-R, et al. Association between total bilirubin and hemoglobin {A}1c in {Korean} type 2 diabetic patients. J Korean Med Sci 2012
  23. 1196–201. doi:10.3346/jkms.2012.27.10.1196.